REFERENCES
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.https://doi.org/10.1056/NEJMoa2001017
2. World Health Organization. Coronavirus disease (COVID-2019) situation reports-102 (1 May 2020). Accessed 15 January 2021.
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China : summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 2020.https://doi.org/10.1001/jama.2020.2648
4. Lang W, Wenbo H, Xiaomei Y, Dalong H, Mingwei B, et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up, J Infection 2020 639–645.https://doi.org/10.1016/j.jinf.2020.03.019
5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513.https://doi.org/10.1016/S0140-6736(20)30211-7
6. Santé Publique France. Point épidémiologique COVID-19 au 21 Mai 2020. Accessed 15 January 2021.
7. Hatah E, Braund R, Tordoff J, Duffull SB. A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. Br J Clin Pharmacol. 2013 Jan;77(1):102-15.https://doi.org/10.1111/bcp.12140
8. Freyer J, Hueter L, Kasprick L, Frese T, Sultzer R, Schiek S, et al. Drug-related problems in geriatric rehabilitation patients after discharge – A prevalence analysis and clinical case scenario-based pilot study. Res Soc Adm Pharm. 2018;14(7):628–37. 21.https://doi.org/10.1016/j.sapharm.2017.07.009
9. Bedouch P, Allenet B, Labarere J, Brudieu E, Chen C, Chevrot D, et al. Diffusion des opinions pharmaceutiques dans le cadre d’une activité de pharmacie Clinique en unité de soins, Therapie, Volume 60, Issue 5, 2005, Pages 515-522.https://doi.org/10.2515/therapie:2005015
10. Gutiérrez-Valencia M, Izquierdo M, Beobide-Telleria I, et al. Medicine optimization strategy in an acute geriatric unit: The pharmacist in the geriatric team. Geriatr Gerontol Int. 2019;19(6):530-536.https://doi.org/10.1111/ggi.13659
11. Hailu BY, Berhe DF, Gudina EK, Gidey K, Getachew M. Drug related problems in admitted geriatric patients: the impact of clinical pharmacist interventions. BMC Geriatr. 2020;20(1):13. Published 2020 Jan 13.https://doi.org/10.1186/s12877-020-1413-7
12. Gillespie U, Alassaad A, Henrohn D, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med. 2009;169(9):894-900. https://doi.org /10.1001/archinternmed.2009.71
13. Juste M. Recommandation de bonne pratique en pharmacie clinique. Analyse d’ordonnance et niveaux d’analyse pharmaceutique. Pharm Hosp Clin 2012;47:293–5.https://doi.org/10.1016/j.phclin.2012.10.082
14. Laroche ML, Bouthier F, Merle L, Charmes JP. Médicaments potentiellement inappropriés aux personnes âgées : intérêt d’une liste adaptée à la pratique médicale française. Rev Med Intern 2009;30:592–601.https://doi.org/10.1016/j.revmed.2008.08.010
15. Lang PO, Dramé M, Guignard B, et al. Les critères STOPP/START.v2 : adaptation en langue française. NPG Neurol Psychiatr Geriatrie 2015;15:323–36.https://doi.org/10.1016/j.npg.2015.08.001
16. Allenet B, Bedouch P, Rose FX, Escofier L, Roubille R, Charpiat B, et al. Validation of
an instrument for the documentation of clinical pharmacists’ interventions. Pharm World Sci. 2006
Aug;28(4):181-8.https://doi.org/10.1007/s11096-006-9027-5
17. Vo TH, Evaluation of the potential impact of pharmacist interventions: development and validation of the CLEO multidimensional tool- Université Grenoble-Alpes (2015).https://tel.archives-ouvertes.fr/tel-01315619
18. Cadogan CA, Hughes CM. On the frontline against COVID-19: Community pharmacists’ contribution during a public health crisis. Res Social Adm Pharm. 2020 Mar 31:S1551-7411(20)30292-8.https://doi.org/10.1016/j.sapharm.2020.03.015
19. Li H, Zheng S, Liu F, Liu W, Zhao R. Fighting against COVID-19: Innovative strategies for clinical pharmacists. Res Social Adm Pharm. 2020 Apr 6:S1551-7411(20)30328-4.https://doi.org/10.1016/j.sapharm.2020.04.003
20. Burgess LH, Cooper MK, Wiggins EH, Miller KM, Murray E, Harris S, Kramer JS. Utilizing Pharmacists to Optimize Medication Management Strategies During the COVID-19 Pandemic. J Pharm Pract. 2020 Oct 5:897190020961655.https://doi.org/10.1177/0897190020961655
21. Surapat B, Sungkanuparph S, Kirdlarp S, Lekpittaya N, Chunnguleum K. Role of clinical pharmacists in telemonitoring for patients with Coronavirus Disease 2019 (COVID-19). J Clin Pharm Ther. 2020 Oct 21.https://doi.org/10.1111/jcpt.13293
22. Collins CD, West N, Sudekum DM, Hecht JP. Perspectives from the frontline: A pharmacy department’s response to the COVID-19 pandemic, AM J Health-Syst PH, Volume 77, Issue 17, 1 September 2020, Pages 1409–1416.
https://doi.org/10.1093/ajhp/zxaa176
23. Perez M, Masse M, Deldicque A, et al. Analysis of clinical pharmacist interventions in the COVID-19 units of a French university hospital. Eur J Hosp Pharm. Published Online First: 11 March 2021.
https://doi.org/10.1136/ejhpharm-2020-002542
24. Raimbault-Chupin M, Spiesser-Robelet L, Guir V et al. Drug related problems and pharmacist interventions in a geriatric unit employing electronic prescribing. Int J Clin Pharm 35, 847–853 (2013).https://doi.org/10.1007/s11096-013-9821-9
25. Chatelet J-N, Thèse en vue du diplôme d’état de Pharmacie, Evaluation de l’impact clinique de la présence pharmaceutique dans le service de court séjour gériatrique au Centre Hospitalier d’Armentières. Université de Lille 2, 2016.
26. Lewis PJ, Dornan, T, Taylor D et al. Prevalence, Incidence and Nature of Prescribing Errors in Hospital Inpatients. Drug-Safety 2009, 32, 379–389.https://doi.org/10.2165/00002018-200932050-00002
27. Courtman B, Stallings S, Characterization of Drug-Related Problems in Elderly Patients on Admission to a Medical Ward. Can J Hosp Pharm 1995; 48:161-166
https://doi.org/10.4212/cjhp.v48i3.2275
28. Castronovo A, Gervais F, Mongaret C, Slimano C, Pharmacists’ interventions on prescription problems in one French community pharmacy: A prospective pilot study, Ann Pharm Fr 2018, 76 (4):299-305.
https://doi.org/10.1016/j.pharma.2018.02.002.
29. Gervais F, Novais T, Goutelle S, Chappuy M, Parat S, Cabelguenne D, et al. Drug-related problems among older patients: Analysis of 8 years of pharmacist’s interventions, Ann Pharm Fr 2021https://doi.org/10.1016/j.pharma.2021.02.002.
30. Paillet-Testart D, Melin N, Bourgoin F, Hocquette D, Dubois J. Enquête achat et consommation des médicaments à l’hôpital : une enquête à découvrir. Rev. épidémiol. santé publique Volume 67, Supplement 2, March 2019, Page S93
31. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007 May 29;115(21):2689-96.https://doi.org/10.1161/circulationaha.106.653048
32. Jansen J, Naganathan V, Carter S M, McLachlan A J, Nickel B, Irwig L et al. Too much medicine in older people? Deprescribing through shared decision making BMJ 2016; 353 :i2893
https://doi.org/10.1136/bmj.i2893
33. Franck C, Erica Weir. Deprescribing for older patients. CMAJ Dec 2014, 186 (18) 1369-1376.https://dx.doi.org/10.1503%2Fcmaj.131873
34. Bertoliatti-Fontana G, Bertho M, Tiret I, Chenailler C, Varin R, Doucet J. Efficacité des interventions pharmaceutiques : comparaison de deux modalités d’analyses pharmaceutiques en médecine interne. Pharm Hosp Clin 2020; 55: 48–55.https://doi.org/10.1016/j.phclin.2019.09.002
35. Reinau D, Furrer C, Stämpfli D, Bornand D, Meier CR. Evaluation of drug-related problems and subsequent clinical pharmacists’ interventions at a Swiss university hospital. J Clin Pharm Ther. 2019;44(6):924-931.
36. Mongaret C, Quillet P, Vo TH, et al. Predictive factors for clinically significant pharmacist interventions at hospital admission. Medicine (Baltimore). 2018;97(9):e9865.http://dx.doi.org/10.1097/MD.0000000000009865
37. Zamparutti P, Nicolle I, Polard E, Le Duff M. Analyse de prescription : 2. Résultats obtenus dans un service de gériatrie. Pharm Hosp Fr. 1997;(119):12-16.
38. Ziane A, Ngami C, Youb R, Hazem Atri M, Aikpa R, Kabirian F, et al. Évaluation de la qualité des interventions pharmaceutiques chez le sujet âgé de plus de 75 ans. J Pharm Clin-Series. 2013;32(4):243-249.https://doi.org/10.1684/jpc.2013.0261
39. Bedouch P, Allenet B, Labarere J, Brudieu E, Chen C, Chevrot D, et al. Diffusion des opinions pharmaceutiques dans le cadre d’une activité de pharmacie clinique en unité de soins. Therapie. 2005;60(5):515–22.https://doi.org/10.2515/therapie:2005015